180 Wealth Advisors LLC Has $173,000 Stock Position in Fortress Biotech, Inc. $FBIO

180 Wealth Advisors LLC grew its stake in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) by 6.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 93,050 shares of the biopharmaceutical company’s stock after purchasing an additional 5,600 shares during the period. 180 Wealth Advisors LLC owned approximately 0.31% of Fortress Biotech worth $173,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. HB Wealth Management LLC raised its holdings in shares of Fortress Biotech by 6.1% during the first quarter. HB Wealth Management LLC now owns 113,350 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 6,500 shares during the period. PFG Investments LLC raised its holdings in shares of Fortress Biotech by 22.4% during the second quarter. PFG Investments LLC now owns 55,419 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 10,160 shares during the period. Weaver Consulting Group raised its holdings in shares of Fortress Biotech by 101.8% during the first quarter. Weaver Consulting Group now owns 46,417 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 23,419 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Fortress Biotech by 11.8% during the first quarter. Envestnet Asset Management Inc. now owns 267,908 shares of the biopharmaceutical company’s stock valued at $418,000 after purchasing an additional 28,314 shares during the period. Finally, Shikiar Asset Management Inc. raised its holdings in shares of Fortress Biotech by 18.0% during the second quarter. Shikiar Asset Management Inc. now owns 278,469 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 42,500 shares during the period. Institutional investors and hedge funds own 96.51% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on FBIO. Wall Street Zen raised shares of Fortress Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fortress Biotech in a research report on Saturday. Finally, HC Wainwright decreased their target price on shares of Fortress Biotech from $26.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, August 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Fortress Biotech presently has a consensus rating of “Hold” and an average price target of $16.50.

Fortress Biotech Trading Down 0.4%

Shares of FBIO stock opened at $2.51 on Monday. Fortress Biotech, Inc. has a 52-week low of $1.33 and a 52-week high of $4.20. The company has a 50-day simple moving average of $3.01 and a two-hundred day simple moving average of $2.23. The company has a market capitalization of $74.67 million, a price-to-earnings ratio of -2.39 and a beta of 1.75. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.70 and a current ratio of 1.92.

Fortress Biotech (NASDAQ:FBIO) last released its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.15). Fortress Biotech had a negative net margin of 24.84% and a negative return on equity of 301.81%. The company had revenue of $16.41 million for the quarter, compared to the consensus estimate of $14.53 million. Research analysts anticipate that Fortress Biotech, Inc. will post -3.28 EPS for the current fiscal year.

Fortress Biotech Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.